INTERNATIONAL PATENT: INNATE PHARMA FILES APPLICATION FOR "USE OF CD39 BLOCKING AGENTS IN COMBINATION WITH ANTI-CD20 X CD3 T CELL ENGAGERS"

GENEVA, Nov. 17 -- INNATE PHARMA (117 Avenue de Luminy13009 Marseille) filed a patent application (PCT/EP2025/062181) for "USE OF CD39 BLOCKING AGENTS IN COMBINATION WITH ANTI-CD20 X CD3 T CELL ENGAGERS" on May 05, 2025. With publication no. WO/2025/233266, the details related to the patent application was published on Nov 13, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): ROIDER, Tobias (Schroderstr. 7269120 Heidelberg), DIETRICH, Sasha (Achillesstrasse 1740545 Duesseldorf), KOLBE, Clara (Kirchfeldstrasse 6940217 Dusseldorf)

Abstract: The present invention relates to agents that inhibit t...